Stock Research for BPTH


Featured Broker: Ally Invest

Get the due diligence for another stock.


BPTH Stock Chart & Research Data

The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BPTH Due diligence Resources & Stock Charts

The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BPTH Detailed Price Forecast - CNN Money CNN View BPTH Detailed Summary - Google Finance
Yahoo View BPTH Detailed Summary - Yahoo! Finance Zacks View BPTH Stock Research & Analysis -

Stock Analysis

TradeIdeas View BPTH Trends & Analysis - Trade-Ideas Barrons View BPTH Major Holders - Barrons
NASDAQ View BPTH Call Transcripts - NASDAQ Seeking View BPTH Breaking News & Analysis - Seeking Alpha
Spotlight View BPTH Annual Report - OTC Report View BPTH OTC Short Report -
TradeKing View BPTH Fundamentals - TradeKing Charts View BPTH SEC Filings - Bar Chart
WSJ View Historical Prices for BPTH - The WSJ Morningstar View Performance/Total Return for BPTH - Morningstar
MarketWatch View the Analyst Estimates for BPTH - MarketWatch CNBC View the Earnings History for BPTH - CNBC
StockMarketWatch View the BPTH Earnings - StockMarketWatch MacroAxis View BPTH Buy or Sell Recommendations - MacroAxis
Bullish View the BPTH Bullish Patterns - American Bulls Short Pains View BPTH Short Pain Metrics -

Social Media Mentions

StockTwits View BPTH Stock Mentions - StockTwits PennyStocks View BPTH Stock Mentions - PennyStockTweets
Twitter View BPTH Stock Mentions - Twitter Invest Hub View BPTH Investment Forum News - Investor Hub
Yahoo View BPTH Stock Mentions - Yahoo! Message Board Seeking Alpha View BPTH Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BPTH - Insider Cow View Insider Transactions for BPTH - Insider Cow
CNBC View BPTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BPTH - OTC Markets
Yahoo View Insider Transactions for BPTH - Yahoo! Finance NASDAQ View Institutional Holdings for BPTH - NASDAQ

Stock Charts

FinViz View BPTH Stock Insight & Charts - StockCharts View BPTH Investment Charts -
BarChart View BPTH Stock Overview & Charts - BarChart Trading View View BPTH User Generated Charts - Trading View

Latest Financial News for BPTH

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
Posted on Tuesday June 26, 2018

DALLAS, TX / ACCESSWIRE / June 26, 2018 / Bio-Path Holdings, Inc. ("Bio-Path") (NASDAQ: BPTH): COMPANY DESCRIPTION Bio-Path Holdings, Inc. (Bio-Path) is a clinical-stage biotechnology company ...

With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s (NASDAQ:BPTH) A Concern?
Posted on Wednesday May 16, 2018

For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

Bio-Path: 1Q Earnings Snapshot
Posted on Wednesday May 16, 2018

The Bellaire, Texas-based company said it had a loss of 17 cents per share. The company's shares closed at $1.76. A year ago, they were trading at $5.31. _____ This story was generated by Automated Insights ...

Bio-Path Holdings Reports First Quarter 2018 Financial Results
Posted on Wednesday May 16, 2018

Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate developments. “Throughout the first quarter of 2018, we made major strides advancing our RNAi nanoparticle drugs for the treatment of a variety of cancers with limited treatment options. Specifically, we were delighted to publish and present data in support of our DNAbilize® technology in both peer-viewed journal articles and at key oncology medical meetings.  In particular, we were delighted with the interim results from our ongoing Phase 2 clinical trial of prexigebersen for the treatment of AML, which showed 47% of evaluable patients demonstrated some degree of response to prexigebersen in combination with LDAC, representing a significant advance for de-novo patients previously untreated for AML who are not otherwise eligible for standard or high-intensity chemotherapy regimens or who have elected a low intensity regimen,” said Peter Nielsen, President and CEO of Bio-Path Holdings.

Enter a stock symbol to view the stock details.